CD34+ cell immunoselection from G-CSF-alone-primed peripheral blood in children with low body mass.
We report the data of CD34+ cell immunoselection from peripheral blood after G-CSF-alone mobilization (10 micrograms/kg/d s.c.) in nine children with neuroblastoma (median age 4-5 years (2-8), median body weight 16 kg (10-20). Leukaphereses were carried out on a Cobe Spectra separator and two consecutive harvests (4 blood volumes processed) were used for immunoselection on a Ceprate column. The yield of CD34+ cells in the purified fraction was 50% (23-80), with a median number of 2.8 x 10(6) CD34+ cells/kg (1-9.4). All patients were reinfused with selected CD34+ cells after busulfan 600 mg/m2 +melphalan 180 mg/m2 and achieved successful haemopoietic recovery.
CHRU, Clermont-Ferrand, France.
J
J
Kanold
M
M
Berger
C
C
Rapatel
L
L
de Lumley
P
P
Lutz
D
D
Plantaz
J P
JP
Vannier
C
C
Bergeron
F
F
Mechinaud
M
M
Favrot
D018952:Antigens, CD34 / Q000276:immunology*; D001835:Body Weight; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007937:Leukapheresis; D008558:Melphalan / Q000627:therapeutic use; D009447:Neuroblastoma / Q000188:drug therapy / Q000276:immunology*
D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D002066:Busulfan; D008558:Melphalan